buy

BeiGene Ltd ADR buy marge

BeiGene Ltd ADR

Startpreis

83,33 €

/ 50%

Kursziel

01.01.19

Rendite (%)

Endpreis

126,51 €

Zusammenfassung

Diese Einschätzung wurde am mit einem Endkurs von 126,51 € beendet. Die BUY Einschätzung von marge überzeugte mit einer Rendite von . marge hat 50% Zuversicht bei dieser Einschätzung

Finanztrends

Rendite ohne Dividenden (%)

Name	1W	1M	1J	3J
BeiGene Ltd ADR
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Kommentare von marge zu dieser Einschätzung

In der Diskussion Beigene Ltd ADR diskutieren

Einschätzung Buy

Rendite (%)

Kursziel 198,44

Veränderung

Endet am

BeiGene is a Buy, as the stock is currently over 25% off its high!

The firm possessed a deep, underappreciated pipeline of promising drug candidates.

Management appeared to be progressing their lead products in an efficient and expeditious manner, with promising phase 1 data presented in June for anti-PD-1 antibody BGB-A317 in combination with their PARP inhibitor BGB-290 in patients with solid tumors. Updated data from an early study of BTK inhibitor BGB-3111 in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) was also quite promising (overall response rate of 94% with very low discontinuation rate of 3%).

Validation came in the form of a global collaboration deal signed with Celgene to commercialize PD-1 inhibitor BGB-A137. The specifics of the deal were interesting, with BeiGene management wisely

retaining exclusive rights in Asia (except Japan) as well as receiving Celgene's commercial operations in China (exclusive license to commercialize Abraxane, Vidaza and Revlimid). BeiGene also received
licensing rights in China to Celgene's next generation CelMod for lymphoma and hepatocellular carcinoma, CC-122. The financial terms were very generous, with BeiGene to receive upfront licensing fees of $263 million. The larger firm purchased 32.7 million shares at $59.55 per ADS (a 35% premium over the 11-day volume-weighted average price at the time).